FdaApplication
NDA 022315
Identifiers
- fda_app_no: NDA022315
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2009-06-17 |
Revenue by product
OZURDEX
| Period | Revenue |
|---|---|
| Q4 2025 | $128.0M |
| Q3 2025 | $117.0M |
| Q2 2025 | $125.0M |
| Q1 2025 | $123.0M |
| Q4 2024 | $120.0M |
| Q3 2024 | $119.0M |
| Q2 2024 | $124.0M |
| Q1 2024 | $131.0M |
| Q4 2023 | $118.0M |
| Q3 2023 | $120.0M |
| Q2 2023 | $119.0M |
| Q1 2023 | $115.0M |
| Q4 2022 | $105.0M |
| Q3 2022 | $106.0M |
| Q2 2022 | $110.0M |
| Q1 2022 | $107.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OZURDEX | DEXAMETHASONE | 0.7MG | IMPLANT;INTRAVITREAL |
1 product